<DOC>
	<DOCNO>NCT01206426</DOCNO>
	<brief_summary>This observational clinical trial study adult urothelial cancer patient treat cisplatin‐based neoadjuvant chemotherapy . Hypothesis : Identification genetic molecular `` cisplatin susceptibility '' biomarkers allow identification urothelial cancer patient likely benefit cisplatin‐based neoadjuvant chemotherapy .</brief_summary>
	<brief_title>Genetic Determinants Response Neoadjuvant Cisplatin-based Chemotherapy Urothelial Cancer</brief_title>
	<detailed_description>In trial patient submit germline ( blood ) tumor tissue sample part two exist sample collection protocol analysis genetic molecular marker govern response chemotherapy . Pathologic review tissue sample neoadjuvant therapy allow determination complete response rate ( pT0 rate ) compare patient `` susceptible '' `` resistant '' genetic/molecular cisplatin susceptibility variant . Primary Endpoint : Analysis whether small set previously‐identified germline `` cisplatin susceptibility '' polymorphism associate achievement complete pathologic response neoadjuvant cisplatin‐based chemotherapy urothelial cancer patient . Secondary Endpoints : To perform companion genetic molecular analysis previously‐identified gene , SNP , microRNA `` cisplatin susceptibility '' candidate patient , use tumor and/or germline tissue . Exploratory Endpoints : To perform unbiased , hypothesis‐generating SNP , gene , microRNA array study identify novel germline tumor determinant may predict response cisplatin‐based chemotherapy .</detailed_description>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Patients clinical T2 T4 urothelial carcinoma bladder upper tract . Patients must deem appropriate treating physician require cisplatinbased neoadjuvant chemotherapy urothelial cancer . Consideration regional nodal status part decision appropriateness neoadjuvant chemotherapy leave treat physician . Patients must schedule proceed definitive urothelial cancer surgery , include either cystectomy nephrectomy/ureterectomy , chemotherapy . Age &gt; 18 year . Patients receive cisplatin‐based chemotherapy urothelial cancer adjuvant set metastatic disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Urothelial , cancer , cisplatin , neoadjuvant , chemotherapy , germline</keyword>
</DOC>